Emerging Diseases


The Chikungunya virus is transmitted to humans via infected mosquitoes and causes large outbreaks with high attack rates. With outbreaks in Africa, America, Asia, Europe, and islands in the Indian and Pacific Oceans the Chikungunya virus is posing a growing risk to citizens and travelers in infected regions of the world. Still no vaccine or preventive drug is available and annual sales for an efficient vaccine are expected to exceed 300 Mio USD annually.

Themis' Chikungunya vaccine candidate already proved its excellent immunogenicity profile as well as its safety and tolerability in a phase I clinical trial. Results showing clear dose responses were published in the 'The Lancet Infectious Diseases' in 2015. The further clinical development is currently progressing well and market approval is expected within the next 2 to 3 years.

See also: 2 March 2015: Themis Bioscience's Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases


In 2016, the World Health Organization (WHO) declared the Zika virus a public health emergency of international concern. Zika virus disease is caused by the Zika virus which is spread through the bite of infected mosquitoes. Outbreaks of Zika have been reported in tropical Africa, Southeast Asia, and the Pacific Islands. As there is currently no vaccine or preventive drug available, options to prevent Zika virus disease are limited.


Dengue is a leading cause of febrile illness among travelers returning from Latin America, the Caribbean, and Southeast Asia. The disease is endemic throughout the tropics and subtropics and occurs in over 100 countries worldwide. There are 4 related single-stranded RNA Dengue viruses and an infection with any of these can cause the diseas.

No vaccine is available against Dengue and no chemoprophylaxis is available to prevent it. There are no specific antiviral agents for dengue.